Sialyl LewisX mimic-decorated liposomes for anti-angiogenic everolimus delivery to E-selectin expressing endothelial cells†

Chanikarn Chantarasrivong, a,b Yuriko Higuchi, a Masahiro Tsuda, a Yuuki Yamane, a Mitsuru Hashida, b Miku Konishi, c Naoko Komura, c Hiromune Ando d e and Fumiyoshi Yamashita a,*

In this study, we developed novel E-selectin-targeting liposomes, i.e., 3′-(1-carboxy)ethyl sialyl LewisX (3′-CE sLeX) mimic liposomes, for targeted delivery of everolimus (EVE) in anti-angiogenic therapy. We investigated the uptake and efficacy of these E-selectin targeting liposomes in inflammatory cytokine-treated human umbilical vein endothelial cells (HUVECs). The uptake of EVE in 3′-CE sLeX mimic liposomes increased steadily and almost caught up with the uptake of plain EVE at 3 h, which was higher than that in PEGylated liposomes (PEG-liposomes). Inhibition of uptake by anti-E-selectin antibody suggested involvement of E-selectin-mediated endocytotic processes. Migration in cells treated with EVE/3′-CE sLeX mimic liposomes was suppressed by more than half when compared to the control. This treatment was also seen to significantly inhibit the formation of capillary tubes and networks. In addition, Thr389 phosphorylation of pS6 kinase, as a marker of mTOR activity, was remarkably suppressed to less than endogenous levels by EVE/3′-CE sLeX mimic liposomes. In conclusion, the present study demonstrated that EVE/3′-CE sLeX mimic liposomes were intracellularly taken up by E-selectin and prompted anti-angiogenic effects of EVE involved in the mTOR signaling pathway. However, moderate retention of EVE in the liposomes might limit the targeting ability of 3′-CE sLeX mimic liposomes.

Introduction

Anti-angiogenic therapy is one of the most effective approaches for the treatment of various types of cancers; this therapy causes damage to the surrounding endothelial cells, which limits oxygen/nutrient supply to tumor cells and results in tumor necrosis. This advantage has led to many studies on anti-angiogenic drugs and their subsequent approval by the FDA for cancer therapy. 1–4 However, anti-angiogenic therapy may induce adaptive tumor microenvironmental defense mechanisms, leading to drug resistance or invasion. 5–7 While combinatorial therapies using different drug targets are suggested to overcome this resistance, 6, 5 attention has also been paid to targeted drug delivery to improve the efficacy of drugs in anti-angiogenic therapy. 8 For example, nanoparticles coated with collagen IV-binding peptides 7 or cyclic RGD peptides 8 were delivered to tumor endothelial cells, thereby improving the antitumorigenic and anti-metastatic activity of cytotoxic drugs in tumor-bearing mice. It has also been demonstrated that paclitaxel conjugated with factor VIIa, which binds to tissue factors expressed aberrantly in the tumor endothelium, suppresses tumor growth in paclitaxel-resistant cancer and inhibits its metastasis. 9

E-selectin is one of the most attractive targets expressed on the tumor endothelium, 10–12 whose expression is strongly induced by cytokines and angiogenic growth factors secreted from tumors to facilitate angiogenesis and subsequent tumor growth/penetration. 13–16 So far, E-selectin-directed drug delivery systems have mostly utilized sialyl LewisX (sLeX), a natural ligand of E-selectin, 17–20 although there are a few exceptions such as anti-E-selectin antibodies, 21 E-selectin-binding peptides, 22 and aptamers. 23 Previously, we synthesized novel sLeX analogs and conjugated them with 1,2-distearyl-sn-glycero-3-phosphoethanolamine-polyethylene glycol-2000 (DSPE-PEG2000) for targeted liposomal delivery. Despite being a structurally simplified trisaccharide analog, the 3′-(1-carboxy)ethyl sLeX (3′-CE sLeX) mimic exhibited higher potency than native sLeX in terms of enhancement of liposome uptake in E-selectin-expressing endothelial cells. 24 The 3′-CE sLeX mimic liposomes appeared promising for the delivery of anti-angiogenic drugs to tumor endothelial cells.
Everolimus (EVE) is an mTOR (mammalian target of rapamycin) inhibitor, which inhibits complex formation of serine/threonine kinase (mTOR) to raptor and mLST8 by binding to the cyclophilin FK binding protein-12. mTOR is generally activated in cancers and plays important roles in multiple cellular processes, especially tumor-relevant angiogenesis, endothelial cell proliferation, survival, and migration.25–29 While several studies showed that EVE inhibits angiogenesis and tumor growth in tumor models,30,31 the low bioavailability and low water solubility of the drug have limited its use. There have been attempts to overcome these drawbacks through the use of liposomes or nanocarriers.32–34 In this study, we used human umbilical vein endothelial cells (HUVECs) activated with inflammatory cytokines as E-selectin-expressing models that imitate the mechanisms promoting tumorigenesis in the tumor microenvironment.35–39 The everolimus-encapsulated 3′-CE sLeX mimic liposomes were prepared and the physicochemical properties, cellular uptake, and pharmacological effects were then investigated.

**Experimental**

**Materials**

1,2-Distearoyl-sn-glycero-3-phosphocholine (DSPC) was purchased from Avanti Polar Lipids (Alabaster, AL, USA). Cholesterol, ethanol, and dimethyl sulfoxide (DMSO) were purchased from Nacalai Tesque (Kyoto, Japan). N-(methyl-polyoxyethylene oxyoxycarbonyl)-1,2-distearoyl-sn-glycero-3-phosphoethanolamine (DSPE-PEG2000) was purchased from NOF Corporation (Tokyo, Japan). 3′-CE sLeX-DSPE-PEG (Fig. 1) were synthesized by the method reported previously.34 EVE was purchased from Chem Scene (South Brunswick Township, NJ, USA). Phosphate-buffered saline (PBS) was purchased from Nissan Pharmaceutical (Tokyo, Japan). TNF-α was purchased from Nissui Pharmaceutical (Tokyo, Japan). 3′-CE sLeX-DSPE-PEG (Fig. 1) were synthesized by the method reported previously.34

**Preparation of EVE-loaded liposomes**

EVE-loaded liposomes were prepared by ethanol injection method.32 DSPC (5.5 μmol), cholesterol (4 μmol), and DSPE-PEG or 3′-CE sLeX-DSPE-PEG (0.5 μmol) were dissolved in 1 mL ethanol heated to 70 °C in a glass tube. Twenty-four microliters of DMSO containing 0.5 μmol EVE was added to the lipid solution and incubated for 3 min at 70 °C. The mixture was rapidly added to 2 mL PBS in a glass vial and stirred at 70 °C for 30 s. The ethanol in the mixture was removed under reduced pressure using a centrifugal evaporator (SpeedVac Concentrator).

**Characterization of EVE-loaded liposomes**

The concentration of phospholipids in the eluate was determined using a HPLC system (Prominence UFLC, Shimadzu Corporation, Kyoto, Japan) equipped with a ZORBAX column (SB-C18 4.6 I.D. × 75 mm, 3.5 μm, Agilent Technologies, Santa Clara, CA, USA), which was maintained at 60 °C. The mobile phase comprised distilled water with 0.1% trifluoroacetic acid and acetonitrile with 20 mM triethylamine and 0.156% trifluoroacetic acid (40 : 60 v/v) and was maintained at a flow rate of 1 mL min⁻¹. The wavelength of detection of EVE was set to 278 nm.

**Cell culture**

Primary HUVECs were cultured in HuMedia-EG2 culture medium, according to the protocol supplied by the manufacturer (Kurabo Industry, Osaka, Japan). When the cells reached 70–80% confluence, they were harvested using trypsin–EDTA, suspended in the culture medium, and plated on a dish. The rest of the cells was maintained in a flask for up to 3 generations. On day 1 after plating, the cells were pretreated with 100 ng mL⁻¹ TNF-α and 10 ng mL⁻¹ IL-1β for 5 h, to induce E-selectin expression.

**Cellular toxicity**

HUVECs were plated at a density of 10 000 cells/100 μL (equivalent to 30 000 cells per cm²) in a 96-well plate. The seeding density was lower than that in other experiments (~50 000 cells per cm²), to make the cells more sensitive in toxicity detection.40 On day 1, following a 5 h cytokine treatment, the cells were treated with EVE or EVE-loaded liposomes at the indicated concentration. After incubating for 3 h, 10 μL of Cell Count Reagent SF (Nacalai Tesque, Kyoto, Japan) was added to the culture medium and the cells were incubated for 2 h. The cell viability was detected colorimetrically using BioTek Eon Microplate Spectrophotometer (Biotek, Winooski, VT, USA) at a wavelength of 450 nm.
Cellular uptake and inhibition by anti E-selectin antibody

HUVECs were plated at a density of 200 000 cells/1 mL (50 000 cells per cm²) in a 12-well plate. On day 1, the cells were 80–90% confluent and used for uptake experiment. After cytokine treatment, EVE or EVE-loaded liposomes were added to the plates at a concentration equivalent to 1 µM EVE. Following incubation for the indicated time periods, the cells were washed with ice cold PBS, scraped off in 100 µL of 10 mM ammonium acetate buffer, and transferred to 1.5 mL tubes. One-hundred microliters of acetonitrile was added to the cell suspension and vortexed for 1 min. After centrifugation at 10 000 × g for 5 min, the supernatant was collected and filtered with 0.45 µm membrane filter. EVE concentration was determined using an LC-MS/MS system (LC-MS-8030, Shimadzu Corporation, Kyoto, Japan). Separation of EVE was achieved on a COSMOSIL 5C18-MS-II column (4.6 mm I.D. Japan). A post column splitter 1 : 4 was installed before the MS interface. EVE was detected using the mass transition m/z 976.45 → 909.60. In contrast, the pellet from the cell lysate was dissolved in 50 µL RIPA buffer (20 mM Tris HCl, 150 mM NaCl, 1 mM EDTA, 1% Triton-X 100, 0.1% SDS, 0.1% Na-deoxycholate), and the protein concentration was measured using Pierce BCA protein assay kit (Thermo Scientific, Rockford, IL, USA) for normalization of cellular uptake.

Inhibition of cell migration

HUVECs were plated at a density of 200 000 cells/500 µL in a 4-well, 35 mm dish (Celvis, Sunnyvale, CA). In this experiment, the cells were seeded at the higher density to become fully confluent on day 1. On day 1, after cytokine treatment, the cell layer was scratched with a 200 µL pipette tip and the culture medium was replaced with medium containing EVE or EVE-loaded liposomes at a concentration equivalent to 1 µM EVE. Live cell imaging was performed every hour for 3 h at 10× magnification using TD (transmitted image) scanning by a confocal microscope (Nikon A1RMP/Ti-E/PFS, Nikon Instruments Inc., Melville, NY, USA) equipped with NIS-elements AR 4.13.00 software. The scratch wound area was determined using Fiji package implemented in ImageJ software. All images were converted to grayscale, and the edges were sharpened and sharpened by the Sobel method. After the threshold was set to obtain a binary image, the edges of wound area were detected with ImageJ’s wand tool. The enclosed area was calculated and expressed as a percentage of initial scratch wound area.

Inhibition of capillary tube formation

Prior to cell seeding, 450 µL of Matrigel (Corning, Bedford, MA, USA) was added to each well in a 2-well chamber slide glass (Matsunami glass Industry, Osaka, Japan) and incubated at 37 °C for 30 min. HUVECs were seeded at a density of 240 000 cells/0.8 mL and incubated at 37 °C. Thirty minutes later, 0.8 mL of culture medium supplemented with 200 ng mL⁻¹ TNF-α and 20 ng mL⁻¹ IL-1β, and 10% Matrigel was added to the chamber well. Five hours later, the EVE or EVE-loaded liposomes at a concentration equivalent to 1 µM EVE were added and incubated for 5 h. The morphology of the cell culture was investigated under a microscope (Biozero, BZ-8100, Kyence Corporation, Osaka, Japan).

Inhibition of mTOR signaling pathway

HUVECs were plated at a density of 500 000 cells/2 mL in a 6-well plate. On day 1, after cytokine treatment, the cells were treated with EVE or EVE-loaded liposomes at a concentration equivalent to 1 µM EVE and incubated at 37 °C for 4 h. To stimulate mTOR signaling, 50 ng mL⁻¹ human epidermal growth factor (hEGF, Cell Signaling Technology, Denver, MA, USA) was added 15 min before the end of incubation, and the cells were washed with ice cold PBS. Eighty microliters of RIPA buffer with Halt phosphatase and protease inhibitor (Thermo Fisher Scientific, Waltham, MA, USA) was added to lyse the cells and the cells lysate was collected with a cell scraper. After centrifugation at 18 000 × g at 4 °C for 20 min, the supernatant was aliquoted and heat-treated at 95 °C for 5 min. The protein concentration was measured using the Pierce BCA protein assay kit. A 15 µg protein aliquot of each sample was subjected to SDS-PAGE on a 12.5% Precast gel (SuperSep Ace, Wako Pure Chemical Industry, Osaka, Japan) and transferred to a PVDF membrane (Immobilon, Merck Millipore, County Cork, Ireland). The membrane was blocked using Tris-buffered saline containing 3% bovine serum albumin (BSA, Sigma Life Science, St. Louis, MO, USA) at 25 °C for 1 h and stained with Phospho-p70 S6 kinase (Thr389) antibody (Cell Signaling Technology, Denver, MA, USA) at a concentration of 1 : 1000 at 4 °C for 1 h as the primary antibody, followed by treatment with horse-radish peroxidase (HRP)-conjugated goat anti-rabbit immunoglobulin G at a concentration of 1 : 10 000 at 25 °C for 1 h (Abcam, Cambridge, U.K.) as the secondary antibody. A β-actin antibody (Santa Cruz Biotechnology, Dallas, TX, USA) was used as loading control at a concentration of 1 : 10 000 at 25 °C for 1 h. All antibodies were diluted in Tris-buffered saline containing 1% BSA. The protein was detected using chemiluminescent HRP substrate (Merck, Billerica, MA) and imaged using ImageQuant LAS 4000 (GE Life Sciences, Buckinghamshire, UK).

Intracellular distribution

Cy5.5-labeled 3′-CE sLeX mimic liposomes were prepared according to the hydration method reported previously. Briefly, DSPC, cholesterol, 3′-CE sLeX mimic-linked DSPE-PEG, and DSPE-PEG-Cy5.5 were mixed in chloroform-methanol (1 : 1) at the molar ratio of 55 : 39 : 5 : 1 and then dried under reduced pressure using a rotary evaporator and vacuum desiccator. The lipid film was swollen and was suspended in PBS at 65 °C. The suspension was sonicated in a bath-type sonicator at 65 °C for 10 min and with a tip-type sonicator for 3 min, and then extruded through a 100 nm pore membrane equipped in an extruder (Avanti Mini-Extruder, Avanti Polar Lipids, Alabaster, AL, USA) maintained at 65 °C. The liposome solution was purified using a PD-10 gel filtration column. To evaluate the
Statistical analysis

Statistical significance was evaluated by one-way or two-way ANOVA followed by the Tukey–Kramer’s post hoc test. The type of ANOVAs adopted was indicated in each figure caption. A value of \( p < 0.05 \) was considered statistically significant.

Results and discussion

Preparation and characterization of EVE-loaded liposomes

The ethanol injection method has been used to prepare EVE- or rapamycin-loaded liposomes.32,44 The EVE-loaded liposomes prepared in this study were comparable in size and drug-to-lipid molar ratio to those in past reports.32,43 Table 1 summarizes characteristics of the prepared liposomes. The average diameter was approximately 80 nm for both EVE/PEG- and EVE/3'-CE sLeX mimic liposomes. Their polydispersity indices were 0.11 and 0.14, indicating that both liposomes have an acceptable uniform size distribution. The EVE/3'-CE sLeX mimic liposome was highly negative with a zeta potential of −26.7 mV, whereas EVE/PEG-liposomes was slightly negative indicating a weaker surface charge. Total lipid recovery of both liposomes was more than 80% confirming no significant loss during preparation. On the other hand, the amount of EVE recovered was 17.97 and 19.90% for EVE/PEG-liposomes and EVE/3'-CE sLeX mimic liposomes, respectively. The low recoveries were associated with recrystallization of overloaded EVE during the ethanol-injection preparation. The drug-to-lipid molar ratio for both liposomes was comparable with the liposomes reported previously.32 The fluorescent labelled 3'-CE sLeX mimic liposomes were prepared by the same method as reported previously.24 Regardless of film hydration or ethanol injection methods, 3'-CE sLeX mimic liposomes prepared possessed basically the same characteristics.

Cellular toxicity

WST-8 assay was carried out to evaluate the cellular toxicity of plain and liposomal EVE and determine the dose used for cellular uptake and anti-angiogenic studies. Fig. 2 shows percent viability of cytokine-treated HUVECs following treatment at different concentrations of the drugs for 3 h. Regardless of treatment with plain or liposomal EVE, the cell viability was more than 80% at concentrations of up to 1 \( \mu \)M. Therefore, 1 \( \mu \)M EVE was chosen for further studies to ensure minimal cell death during the experiment. The designated concentration was consistent with past studies30,34 that had investigated an inhibitory effect of EVE on angiogenesis-related endothelial functions in HUVECs.

Cellular uptake

The uptake of plain or liposomal EVE in HUVECs treated with proinflammatory cytokines was investigated. As shown in Fig. 3, cellular uptake of EVE was the highest with plain EVE, followed

![Fig. 2. WST-8 assay for cellular toxicity of EVE or EVE-loaded liposomes in HUVECs treated with TNF-α and IL-1β. Following 5 h cytokine pretreatment, the cells were incubated with plain or liposomal EVE for 3 h and with WST-8 reagent for an additional 2 h. Symbols: □, plain EVE; △, EVE/PEG-liposomes; ○, EVE/3'-CE sLeX mimic liposomes. Results are expressed as mean ± SD of three samples.](image)

| Liposomes                        | Average diameter (nm) | Polydispersity index | Zeta potential (mV) | Drug recovery (%) | Total lipid recovery (%) | Drug-to-lipid molar ratio |
|----------------------------------|-----------------------|----------------------|---------------------|-------------------|--------------------------|--------------------------|
| EVE/PEG                          | 80.90 ± 8.17          | 0.11 ± 0.06          | −11.62 ± 2.09       | 17.97 ± 2.43      | 84.01 ± 6.04             | 0.015 ± 0.003            |
| EVE/3'-CE sLeX mimic             | 80.28 ± 11.93         | 0.14 ± 0.06          | −26.70 ± 2.66       | 19.90 ± 5.48      | 85.68 ± 4.32             | 0.016 ± 0.001            |
| Cy5.5-labeled 3'-CE sLeX mimic   | 87.58 ± 7.00          | 0.08 ± 0.02          | −25.21 ± 2.95       | —                 | 91.62 ± 2.90             | —                        |

[Table 1 Liposomes characteristics](#)

* Results are expressed as mean ± SD of three samples.
by EVE/3'-CE sLeX mimic liposomes, and then EVE/PEG-liposomes. When plain EVE was administered, the uptake appeared to reach a plateau within almost 1 h. The relatively rapid equilibrium achieved with plain EVE is associated with the mechanism of simple diffusion across the plasma membrane in accordance with the lipophilic nature of EVE. In contrast, the uptake of EVE/3'-CE sLeX mimic liposomes increased steadily over 3 h and almost caught up with plain EVE. We have previously reported that fluorescein-labeled 3'-CE sLeX mimic liposomes have been taken up by E-selectin-mediated endocytotic processes.\textsuperscript{44} The specialized process involving cytotopic membrane transport could be slower than simple diffusion of small lipophilic molecules. The uptake of EVE/3'-CE sLeX mimic liposomes was significantly higher than that of EVE/PEG-liposomes, but the difference between the two liposome formulations was not so large as that seen with fluorescein-labeled liposomes in the previous study. Leakage of EVE from liposomes could not be ruled out (see ESI†). Although a dialysis release experiment might be hampered by adsorption onto membranes, it appeared that the release of EVE from the liposome formulations was biphasic with an initial burst followed by a slow release. The convex-shaped profile for the uptake of EVE/PEG-liposomes similar to that of plain EVE (Fig. 3) might result from the uptake of EVE liberated during the burst phase. The initial-burst release appeared more remarkable with EVE/3'-CE sLeX mimic liposomes (Fig. S1†), but nevertheless the uptake of EVE from the liposomes lasted more than 1 h (Fig. 3). It suggests that drug molecules remaining in 3'-CE sLeX mimic liposomes might be taken up efficiently via the receptor-mediated endocytotic pathway.

To clarify the involvement of the E-selectin-mediated uptake process, the effect of anti-E-selectin antibody on cellular uptake was investigated. Although sLeX is a ligand of E-selectin, P-selectin, and L-selectin\textsuperscript{44,45} only E-selectin blockade was tested, because our previous study\textsuperscript{44} concluded that cellular association of 3'-CE sLeX mimic liposomes be not affected by anti-P-selectin and anti-L-selectin antibodies. Fig. 4 shows that the uptake of EVE/3'-CE sLeX mimic liposomes was significantly inhibited in the presence of anti-E-selectin antibody, whereas it was not observed with either EVE/PEG-liposomes or plain EVE. Interestingly, the uptake of EVE/3'-CE sLeX mimic liposomes under antibody blockade was comparable to that of EVE/PEG-liposomes, implying that the release of EVE from liposome formulations, if any, was not different between the two. Therefore, the improved uptake of EVE/3'-CE sLeX mimic liposomes would be primarily due to an E-selectin-mediated uptake process.

Anti-angiogenic effect

The main endothelial functions involved in angiogenesis are cell migration and capillary tube formation. Cell migration plays an important role in the initial steps of angiogenesis, starting with basement membrane break down and followed by mitosis and migration in response to angiogenic factors including VEGF. After migration, endothelial cells initiate tube formation and develop new vessels to complete angiogenesis.\textsuperscript{46,47} To investigate the anti-angiogenic effect of plain and liposomal EVE, a scratch assay and capillary tube formation were conducted. Moreover, the regulation of the mTOR cascade was confirmed by the degree of Thr389 phosphorylation of pS6 kinase (Ser235/236).

Migration of cytokine-treated HUVECs in the presence of EVE or EVE-loaded liposomes was evaluated in a scratch assay. Fig. 5 shows the percentage of wound closure within 3 h incubation with EVE or EVE-loaded liposomes. The control cells, \textit{i.e.}, HUVECs treated with TNF-\textgamma and IL-1\textbeta, showed 36.2% wound closure within 3 h. However, treatment with plain EVE and EVE/3'-CE sLeX mimic liposomes suppressed the wound closure by more than half (12% and 15.5%, respectively). The suppressive
The rate of migration slowed down following the onset of treatment and almost zero at 48 h. However, the longer time of incubation might have reduced the degree of suppression by 1 μM EVE of ~35% at 24 h. By improving the detection sensitivity to the drug effect, we could more easily evaluate whether the influence of liposomal formulations was accelerative or suppressive.

Tube formation assay is another popular in vitro method to evaluate angiogenesis. It utilizes the nature of endothelial progenitor cells such as HUVECs that form tubes when placed on a 3D extracellular matrix. One micromolar EVE has been known to inhibit tube formation of HUVECs in several reports.\(^{30,34}\) Fig. 6 shows the effect of plain EVE and EVE-loaded liposomes on tube formation. Formation of tubes and networks from cytokine-treated HUVECs was significantly inhibited by plain EVE and EVE/3’-CE sLeX mimic liposomes after 5 h of exposure, whereas the EVE/PEG-liposomes did not significantly interrupt the formation. Morphology of the tube formation in this experiment and other studies\(^{30,34}\) are consistent, control cells formed completed ring, whereas everolimus-treated cells showed disrupted-branches of tube formation.

Western blot analysis was performed to confirm phosphorylation of pS6 kinase at Thr389 amino acid residues, which is a downstream target of EVE in the mTOR signaling pathway.\(^{49}\) Phosphorylation of pS6 kinase was induced by EGF according to the method described by Damiano V., et al.,\(^{30}\) in addition to TNF-α and IL-1β.\(^{49–51}\) Although Damiano, et al.,\(^{30}\) incubated HUVECs with EVE for 24 h, we shortened the time of incubation to 4 h to minimize a pharmacological effect due to EVE leaked from the liposomes. As shown in Fig. 7, treatment with plain EVE and EVE/3’-CE sLeX mimic liposomes remarkably suppressed phosphorylation of pS6 kinase to less than the endogenous level. The four-hour incubation appeared to be enough for EVE to modulate the kinase activity.

EVE/PEG-liposomes suppressed phosphorylation of pS6 kinase (p70) but not that of pS6 kinase (p85). pS6 kinase (p85) is a splicing variant of pS6 kinase (p70), having 23 extra amino acids at the amino-terminus. Since the additional peptide sequence encodes a nuclear localizing signal, pS6 kinase (p85) is exclusively localized in the nuclei.\(^{30,32,53}\)

The difference in subcellular localization or protein structure between the two S6 kinases might relate to the differential effect of EVE/PEG-liposomes was moderate, resulting in 24.3% wound closure. These trends regarding suppression of cell migration were in agreement with cellular uptake of EVE from each formulation. Damiano et al. also found that 1 μM EVE was effective for suppression of HUVEC migration.\(^{30}\) According to their results, the degree of suppression was ~35% at 24 h following the onset of treatment and almost zero at 48 h. However, the longer time of incubation might have reduced the estimate of the drug effect because of the limitation of available area for cell migration. Indeed, real-time monitoring of HUVEC migration has indicated that the index of migration increased linearly up to 3 h and the rate of migration slowed down thereafter.\(^{44}\) In this experiment, the incubation time of 3 h gave the degree of suppression by 1 μM plain EVE of ~67%. By improving the detection sensitivity to the drug effect, we could more easily evaluate whether the influence of liposomal formulations was accelerative or suppressive.

Tube formation assay is another popular in vitro method to evaluate angiogenesis. It utilizes the nature of endothelial progenitor cells such as HUVECs that form tubes when placed on a 3D extracellular matrix. One micromolar EVE has been known to inhibit tube formation of HUVECs in several reports.\(^{30,34}\) Fig. 6 shows the effect of plain EVE and EVE-loaded liposomes on tube formation. Formation of tubes and networks from cytokine-treated HUVECs was significantly inhibited by plain EVE and EVE/3’-CE sLeX mimic liposomes after 5 h of exposure, whereas the EVE/PEG-liposomes did not significantly interrupt the formation. Morphology of the tube formation in this experiment and other studies\(^{30,34}\) are consistent, control cells formed completed ring, whereas everolimus-treated cells showed disrupted-branches of tube formation.

Western blot analysis was performed to confirm phosphorylation of pS6 kinase at Thr389 amino acid residues, which is a downstream target of EVE in the mTOR signaling pathway.\(^{49}\) Phosphorylation of pS6 kinase was induced by EGF according to the method described by Damiano V., et al.,\(^{30}\) in addition to TNF-α and IL-1β.\(^{49–51}\) Although Damiano, et al.,\(^{30}\) incubated HUVECs with EVE for 24 h, we shortened the time of incubation to 4 h to minimize a pharmacological effect due to EVE leaked from the liposomes. As shown in Fig. 7, treatment with plain EVE and EVE/3’-CE sLeX mimic liposomes remarkably suppressed phosphorylation of pS6 kinase to less than the endogenous level. The four-hour incubation appeared to be enough for EVE to modulate the kinase activity.

EVE/PEG-liposomes suppressed phosphorylation of pS6 kinase (p70) but not that of pS6 kinase (p85). pS6 kinase (p85) is a splicing variant of pS6 kinase (p70), having 23 extra amino acids at the amino-terminus. Since the additional peptide sequence encodes a nuclear localizing signal, pS6 kinase (p85) is exclusively localized in the nuclei.\(^{30,32,53}\)

The difference in subcellular localization or protein structure between the two S6 kinases might relate to the differential...
suppression of phosphorylation observed with EVE/PEG-liposomes, which could be emphasized only when the suppressive effect was mild. Nevertheless, a high correlation between cellular uptake, cell migration, tube formation, and phosphorylation of pS6 kinases implied that not only plain EVE but liposomal EVE are likely to suppress angiogenesis via mTOR signaling pathway.

Intracellular distribution

Considering the uncertain observation that E-selectin-targeted liposomes are transported intracellularly via clathrin-independent pathways followed by transport to the Golgi bodies and endoplasmic reticulum or the endosome/lysosome pathway followed by release in the cytoplasm, intracellular disposition behavior of 3'-CE sLeX mimic liposomes was also investigated.

Confocal fluorescence microscopy was employed to clarify subcellular distribution of fluorescence-labeled 3'-CE sLeX mimic liposomes. As shown in Fig. 8, red fluorescence signal associated with 3'-CE sLeX mimic liposomes increased over time. The images indicating such gradual uptake of 3'-CE sLeX mimic liposomes corresponded to the result of quantification of EVE by LC-MS/MS (Fig. 3), as well as our previous observation. The previous study was not conclusive in terms of subcellular localization of the liposomes because of low resolution and no subcellular staining, but Fig. 8 clearly indicates that the liposomes appear to be transported preferentially to lysosomes than to the Golgi bodies.

Taking all findings together, it was suggested that EVE/3'-CE sLeX mimic liposomes are taken up and disassembled in an endosome/lysosome pathway, leading to the release of EVE in the cytoplasm. Our result that sLeX-liposomes are not directly transported to the nucleus are in agreement with the conclusion of Stahn et al.

Conclusion

The present study demonstrated that EVE/3'-CE sLeX mimic liposomes were intracellularly taken up by E-selectin and prompted an anti-angiogenic effect of EVE involved in the mTOR signaling pathway. However, the effectiveness of 3'-CE sLeX mimic liposomes was limited in case of the delivery of EVE, presumably due to moderate retention of the drug. The drug delivery potential of 3'-CE sLeX mimic liposomes and the formulations of EVE need to be further investigated and optimized.

Conflicts of interest

There are no conflicts to declare.

Acknowledgements

This work was financially supported in part by JSPS KAKENHI under grant numbers JP16H01861 (MH) and 18H03531 (FY) and the Research on Development of New Drugs from Japan Agency for Medical Research and Development, AMED under grant number JP19ak0101081 (FY).

References

1. T. Li, G. Kang, T. Wang and H. Huang, Tumor angiogenesis and anti-angiogenic gene therapy for cancer, Oncol. Lett., 2018, 16, 687–702.
2. A. Dutour and M. Rigaud, Tumor endothelial cells are targets for selective therapies: in vitro and in vivo models to evaluate antiangiogenic strategies, Anticancer Res., 2005, 25, 3799–3808.
3. R. S. Samant and L. A. Shevde, Recent advances in anti-angiogenic therapy of cancer, Oncotarget, 2011, 2, 122–134.
4. G. Bergers and D. Hanahan, Modes of resistance to anti-angiogenic therapy, Nat. Rev. Cancer, 2008, 8, 592–603.
5. S. Ma, S. Pradeep, W. Hu, D. Zhang, R. Coleman and A. Sood, The role of tumor microenvironment in resistance to antiangiogenic therapy, F1000Research, 2018, 326(7), 1–19.
6. A. M. E. Abdalla, L. Xiao, M. W. Ullah, M. Yu, C. Ouyang and G. Yang, Current challenges of cancer anti-angiogenic...
therapy and the promise of nanotherapeutics, Theranostics, 2018, 8(2), 533–548.

7 F. Tan, X. H. Mo, J. Zhao, H. Liang, Z. J. Chen and X. L. Wang, A novel delivery vector for targeted delivery of the antiangiogenic drug paclitaxel to angiogenic blood vessels: TLYTTWS-conjugated PEG–PLA nanoparticles, J. Nanopart. Res., 2017, 19, 51.

8 E. A. Murphy, B. K. Majeti, L. A. Barnes, M. Makale, S. M. Weis, K. Luku-Fuga, W. Wrasidlo and D. A. Cheresh, Nanoparticle-mediated drug delivery to tumor vasculature suppresses metastasis, Proc. Natl. Acad. Sci. U. S. A., 2008, 105, 9343–9348.

9 S. Zhu, W. Kisiel, Y. J. Lu, L. C. Petersen, J. M. Ndungu, T. W. Moore, E. T. Parker, A. Sun, D. C. Liotta, B. F. El-Rayes, D. J. Brat, J. P. Snyder and M. Shoi, Tumor angiogenesis therapy using targeted delivery of paclitaxel to the vasculature of breast cancer metastases, J. Drug Deliv., 2014, 2015, e567322.

10 V. Bhaskar, D. A. Law, E. Ibsen, D. Breinberg, K. M. Cass, R. B. DuBridge, F. Evangelista, S. M. Henshall, P. Hevezi, J. C. Miller, M. Pong, R. Powers, P. Senter, D. Stockett, R. L. Sutherland, U. von Freeden-Jeffry, D. Willhite, R. Murray, D. E. Afar and V. Ramakrishnan, E-selectin up-regulation allows for targeted drug delivery in prostate cancer, Cancer Res., 2003, 63, 6387–6394.

11 S. R. Barthel, J. D. Gavino, L. Descheny and C. J. Dimitroff, Targeting selectins and selectin ligands in inflammation and cancer, Expert Opin. Ther. Targets, 2007, 11, 1473–1491.

12 H. Kang, L. Josephson, A. Petrovsky, R. Weissleder and A. Bogdanov Jr, Magnetic resonance imaging of inducible E-selectin expression in human endothelial cell culture, Bioconjugate Chem., 2002, 13, 122–127.

13 A. L. Harris, Antiangiogenesis for cancer therapy, Lancet, 1997, 349, 13–15.

14 S. Hiratsuka, S. Goel, W. S. Kamoun, Y. Maru, D. Fukumura, D. G. Duda and R. K. Jain, Endothelial focal adhesion kinase mediates cancer cell homing to discrete regions of the lungs via E-selectin up-regulation, Proc. Natl. Acad. Sci. U. S. A., 2011, 108(9), 3725–3730.

15 A. M. Khatib, L. Fallavollita, E. V. Wancewicz, B. P. Monia and P. Brodt, Inhibition of hepatic endothelial E-selectin expression by C-raf antisense oligonucleotides blocks colorectal carcinoma liver metastasis, Cancer Res., 2002, 62, 5393–5398.

16 Y. Shamay, L. Raviv, M. Golan, E. Voronov, R. N. Apte and A. David, Inhibition of primary and metastatic tumors in mice by E-selectin-targeted polymer–drug conjugates, J. Controlled Release, 2015, 217, 102–112.

17 N. Hashida, N. Ohguro, N. Yamazaki, Y. Arakawa, E. Oiki, H. Mashimo, N. Kurokawa and Y. Tano, High-efficacy site-directed drug delivery system using sialyl-Lewis X conjugated liposome, Exp. Eye Res., 2008, 86(1), 138–149.

18 E. L. Vodovozova, E. V. Moiseeva, G. K. Grechko, G. P. Gayenko, N. E. Nifant’ev, N. V. Bovin and J. G. Molotkovsky, Antitumour activity of cytotoxic liposomes equipped with selectin ligand SiaLe(X), in a mouse mammary adenocarcinoma model, Eur. J. Cancer, 2000, 36(7), 942–949.

19 M. Hirai, H. Minematsu, Y. Hiramatsu, H. Kitagawa, T. Otani, S. Iwashita, T. Kudoh, L. Chen, Y. Li, M. Okada, D. S. Salomon, K. Igarashi, M. Chikuma and M. Seno, Novel and simple loading procedure of cisplatin into liposomes and targeting tumor endothelial cells, Int. J. Pharm., 2010, 391(1–2), 274–283.

20 E. Jubeli, L. Moine, J. V. Gauduchon and G. Barratt, E-selectin as a target for drug delivery and molecular imaging, J. Controlled Release, 2012, 158, 194–206.

21 C. B. Pattillo, B. Venegas, F. J. Donelson, L. Del Valle, L. C. Knight, P. L. Chong and M. F. Kiani, Radiation-guided targeting of combretastatin encapsulated immunoliposomes to mammary tumors, Pharm. Res., 2009, 26(5), 1093–1100.

22 Y. Shamay, D. Paulin, D. Ashkenasy and A. David, E-selectin binding peptide-polymer-drug conjugates and their selective cytotoxicity against vascular endothelial cells, Biomaterials, 2009, 30(32), 6460–6468.

23 A. P. Mann, A. Somasunderam, R. Nieves-Alicea, X. Li, A. Hu, A. K. Sood, M. Ferrari, D. G. Gorenstein and T. Tanaka, Identification of thiopaptamer ligand against E-selectin: potential application for inflamed vasculature targeting, PLoS One, 2010, 5(9), e13050.

24 C. Chantarasrivong, A. Ueki, R. Ohyama, J. Unga, S. Nakamura, I. Nakanishi, Y. Higuchi, S. Kawakami, H. Ando, A. Imamura, H. Ishida, F. Yamashita, M. Kiso and M. Hashida, Synthesis and functional characterization of novel sialyl lewix mimic-decorated liposomes for e-selectin-mediated targeting to inflamed endothelial cells, Mol. Pharm., 2017, 14, 1528–1537.

25 H. A. Lane, J. M. Wood, P. M. McSheehy, P. R. Allegrini, A. Boulay, J. Brueggen, A. Littlewood-Evans, S. M. Maira, G. Martiny-Baron, C. R. Schnell, P. Sini and T. O’Reilly, mTOR Inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor, Clin. Cancer Res., 2009, 15(5), 1612–1622.

26 L. H. Meng and X. S. Zheng, Toward rapamycin analog (rapalog)-based precision cancer therapy, Acta Pharmacol. Sin., 2015, 36, 1163–1169.

27 P. J. Houghton, Everolimus, Clin. Cancer Res., 2010, 16(5), 1368–1372.

28 S. Faes, T. Santoro, N. Demartines and O. Dormond, Evolving significance and future relevance of anti-angiogenic activity of mTOR inhibitors in cancer therapy, Cancers, 2017, 9, 152.

29 A. Albini, F. Tosetti, V. W. Li, D. M. Noonan and W. W. Li, Cancer prevention by targeting angiogenesis, Nat. Rev. Clin. Oncol., 2012, 1–12.

30 V. Damiano, R. Rosa, L. Formisano, L. Nappi, T. Gelardi, R. Marciano, I. Cozzolino, G. Troncone, S. Agrawal, B. M. Veneziani, S. De Placido, R. Bianco and G. Tortora, Toll-like receptor 9 agonist IMO cooperates with everolimus in renal cell carcinoma by interfering with tumour growth and angiogenesis, Br. J. Cancer, 2013, 108, 1616–1623.
31. Y. Pignochino, C. Dell’Aglio, M. Basiricò, F. Capozzi, M. Soster, S. Marchiò, S. Bruno, L. Gammatoni, D. Sangiolo, E. Torchiaro, L. D’Ambrosio, F. Fagioli, S. Ferrari, M. Alberghini, P. Picci, M. Aglietta and G. Grignani, The Combination of Sorafenib and Everolimus Abrogates mTORC1 and mTORC2 Upregulation in Osteosarcoma Preclinical Models, Clin. Cancer Res., 2013, 19(8), 2117–2131.

32. Y. Iwase and Y. Maitani, Preparation and in vivo evaluation of liposomal everolimus for lung cancer and thyroid carcinoma, Biol. Pharm. Bull., 2012, 35(6), 975–979.

33. M. Kasper, D. Gabriel, M. Möller, D. Bauer, L. Wildschütz, H. Courtthion, M. R. R. Böhm, M. Busch, K. Loser, S. Thanos, R. Gurny and A. Heiligenhaus, Novel everolimus-loaded nanocarriers for topical treatment of murine experimental autoimmune uveoretinitis (EAU), Exp. Eye Res., 2018, 168, 49–56.

34. G. P. Mishra, B. S. Doddapaneni, D. Nguyen and A. W. Alani, Antiangiogenic effect of docetaxel and everolimus as individual and dual-drug-loaded micellar nanocarriers, Pharm. Res., 2014, 3, 660–669.

35. B. Pezeshkian, C. Donnelly, K. Tamburo, T. Geddes and G. J. Madlambayan, Leukemia Mediated Endothelial Cell Activation Modulates Leukemia Cell Susceptibility to Chemotherapy through a Positive Feedback Loop Mechanism, PLoS One, 2013, 8(4), e60823.

36. C. Eichbaum, A. S. Meyer, E. Bischofs, A. Steinborn, T. Bruckner, P. Brodt, C. Sohn and M. H. R. Eichbaum, Breast cancer cell-derived cytokines, macrophages and cell adhesion: implications for metastasis, Anticancer Res., 2011, 31, 3219–3228.

37. T. Narita, N. K. Kimura, Y. Kasai, J. Hosono, T. Nakashio, N. Matsuura, M. Sato and R. Kannagi, Induction of E-selectin expression on vascular endothelium by digestive system cancer cells, J. Gastroenterol., 1996, 31, 299–301.

38. E. Bischofs, D. Lubs, F. Fritzschke, A. S. Meyer, T. Bruckner, C. Sohn and M. H. R. Eichbaum, In vitro blockade of adhesion of breast cancer cells to endothelial cells using anti-inflammatory drugs, Anticancer Res., 2012, 32(3), 767–771.

39. H. Bachtarzi, M. Stevenson, V. Šubr, K. Ulbrich, L. W. Seymour and K. D. Fisher, Targeting adenovirus gene delivery to activated tumour-associated vasculature via endothelial selectins, J. Controlled Release, 2011, 150, 196–203.

40. K. C. S. Gasque, L. P. Al-Ahj, R. C. Oliveira and A. C. Magalhães, Cell Density and Solvent are Critical Parameters Affecting Formazan Evaluation in MTT Assay, Braz. Arch. Biol. Technol., 2014, 57(3), 381–385.

41. Z. L. Miao, Y. J. Deng, H. Y. Du, X. B. Suo, X. Y. Wang, X. Wang, L. Wang, L. J. Cui and N. Duan, Preparation of a liposomal delivery system and its in vitro release of rapamycin, Exp. Ther. Med., 2015, 9(3), 941–946.

42. M. A. L. Alba, M. B. G. Guajardo, J. F. Fonzar, D. E. Brooks, G. A. G. Sánchez and M. J. B. Bernad, Preformulation studies of a liposomal formulation containing sirolimus for the treatment of dry eye disease, J. Ocul. Pharmacol. Ther., 2016, 32(1), 11–22.

43. S. Gholizadeh, G. R. R. Visweswaran, G. Storm, W. E. Hennink, J. A. A. M. Kamps and R. J. Kok, E-selectin targeted immunoliposomes for rapamycin delivery to activated endothelial cells, Int. J. Pharm., 2018, 548, 759–770.

44. P. Malý, A. D. Thall, B. Petryniak, C. E. Rogers, P. L. Smith, R. M. Marks, R. J. Kelly, K. M. Gersten, G. Cheng, T. L. Saunders, S. A. Camper, R. T. Camphausen, F. X. Sullivan, Y. Isogai, O. Hindsaul, U. H. von Andrian and J. B. Lowe, The α(1,3) Fucosyltransferase Fuc-TVII Controls Leukocyte Trafficking through an Essential Role in L-, E-, and P-selectin Ligand Biosynthesis, Cell, 1996, 86, 643–653.

45. K. Neelu and E. T. Bert, Design and Synthesis of Sialyl Lewis x Mimics as E- and P-Selectin Inhibitors, Med. Res. Rev., 2002, 22, 566–601.

46. A. Albini, R. Benelli, D. M. Noonan and C. Brigati, The “chemoinvasion assay”: a tool to study tumor and endothelial cell invasion of basement membranes, Int. J. Dev. Biol., 2004, 58, 563–571.

47. Z. Tahergorabi and M. Khazaei, A review on angiogenesis and its assays, Iran. J. Basic Med. Sci., 2012, 15(6), 1110–1126.

48. M. Matsuki, Y. Adachi, Y. Ozawa, T. Kimura, T. Hoshi, K. Okamoto, O. Toyohama, K. Mitsuhashi, A. Yamaguchi, J. Matsui and Y. Funahashi, Targeting of tumor growth and angiogenesis underlies the enhanced antitumor activity of lenvatinib in combination with everolimus, Cancer Sci., 2017, 108(4), 763–771.

49. L. W. Kraiss, A. S. Weyrich, N. M. Alto, D. A. Dixon, T. M. Ennis, V. Modur, T. M. McNulty, S. M. Prescott and G. A. Zimmerman, Fluid flow activates a regulator of translation, p70/s6 kinase, in human endothelial cells, Am. J. Physiol.: Heart Circ. Physiol., 2000, 278, H1537–H1544.

50. D. F. Lee, H. P. Kuo, C. T. Chen, J. M. Hsu, C. K. Chou, Y. Wei, H. L. Sun, L. Y. Li, B. Ping, W. C. Huang, X. He, J. Y. Hung, C. C. Lai, Q. Ding, J. L. Su, J. Y. Yang, A. A. Sahin, G. N. Hortobagyi, F. J. Tsai, C. H. Tsai and M. C. Hung, IKKb suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway, Cell, 2007, 130, 440–455.

51. J. Zhang, Z. Gao, J. Yin, M. J. Quon and J. Ye, S6K directly phosphorylates IRS-1 on Ser-271 to promote insulin resistance in response to TNF-α signaling through I KK2, J. Biol. Chem., 2008, 283, 35375–35382.

52. B. Magnuson, B. Ekim and D. C. Fingar, Regulation and function of ribosomal protein S6 kinase (S6K) within mTOR signalling networks, Biochem. J., 2012, 441, 1–21.

53. M. Pende, S. H. Um, V. Mieulet, M. Sticker, V. L. Goss, J. Mestan, M. Mueller, S. Fumagalli, S. C. Kozma and G. Thomas, S6K1–/–/S6K2–/– mice exhibit perinatal lethality and rapamycin-sensitive 5-terminal oligopyrimidine mRNA translation and reveal a mitogen-activated protein kinase-dependent S6 kinase pathway, Mol. Cell. Biol., 2004, 24(8), 3112–3124.

54. A. Alekseeva, M. Kapkaeva, O. Shcheglovitova, I. Boldyrev, G. Pazymina, N. Bovin and E. Vodovozova, Interactions of
antitumour sialyl Lewis X liposomes with vascular endothelial cells, Biochim. Biophys. Acta, 2015, 1848, 1099–1110.

55 D. D. Spragg, D. R. Alford, R. Greferath, C. E. Larsen, K. D. Lee, G. C. Gurtner, M. I. Cybulsky, P. F. Tosi, C. Nicolau and M. A. Gimbrone Jr, Immunotargeting of liposomes to activated vascular endothelial cells: a strategy for site-selective delivery in the cardiovascular system, Proc. Natl. Acad. Sci. U. S. A., 1997, 94, 8795–8800.

56 S. Kessner, A. Krause, U. Rothe and G. Bendas, Investigation of the cellular uptake of E-selectin-targeted immunoliposomes by activated human endothelial cells, Biochim. Biophys. Acta, 2001, 1514, 177–190.

57 S. Stahn, C. Grittner, R. Zeisig, U. Karsten, S. B. Felix and K. Wenzel, Sialyl Lewisx-liposomes as vehicles for site-directed, E-selectin-mediated drug transfer into activated endothelial cells, Cell. Mol. Life Sci., 2001, 58, 141–147.